Published in Rev Urol on January 01, 2006
Re: Pathologic guidelines for orthotopic urinary diversion in women with bladder cancer: a review of the literature. Eur Urol (2007) 0.75
[Therapy and follow-up of bladder cancer]. Wien Med Wochenschr (2007) 0.75
Cancer statistics, 2005. CA Cancer J Clin (2005) 25.65
Urethra-sparing cystectomy and orthotopic urinary diversion in women with malignant pelvic tumors. Cancer (2001) 1.58
Urethral recurrence of transitional cell carcinoma in a female patient after cystectomy and orthotopic ileal neobladder. J Urol (2000) 1.45
Indications for lower urinary tract reconstruction in women after cystectomy for bladder cancer: a pathological review of female cystectomy specimens. J Urol (1995) 1.38
Ileal orthotopic bladder substitutes. What we have learned from 12 years' experience with 200 patients. Urol Clin North Am (1997) 1.15
Urethral recurrence in patients with orthotopic ileal neobladders. J Urol (1996) 1.11
Papillomatosis of the urethra. Br J Urol (1956) 1.08
Urethral recurrence in patients following orthotopic urinary diversion. J Urol (2004) 1.01
Prospective pathologic analysis of female cystectomy specimens: risk factors for orthotopic diversion in women. Urology (1998) 1.00
Indications and technique of the orthotopic neobladder in women. Urol Clin North Am (2002) 0.92
The epithelial lining of the female trigone and urethra. Br J Urol (1971) 0.90
The risk of urethral tumors in female bladder cancer: can the urethra be used for orthotopic reconstruction of the lower urinary tract? J Urol (1995) 0.89
Orthotopic bladder substitution in women: nontraditional applications. J Urol (2004) 0.89
Urethral involvement in female bladder cancer patients: mapping of 47 consecutive cysto-urethrectomy specimens. J Urol (1994) 0.88
Local urethral recurrence after radical cystectomy and orthotopic bladder substitution in women: a prospective study. J Urol (2004) 0.86
Urethral involvement in female patients with bladder cancer. A study of 22 cystectomy specimens. Cancer (1990) 0.85
Transitional cell carcinoma of the urethra in men having cystectomy for bladder cancer. J Urol (1976) 0.83
Orthotopic bladder reconstruction in women--what we have learned over the last decade. Crit Rev Oncol Hematol (2003) 0.82
Incidence of urethral involvement in female bladder cancer: an anatomic pathologic study. Urology (1997) 0.81
Carcinoma in situ of the urethra associated with bladder carcinoma: the role of urethrectomy. J Urol (1978) 0.80
Urethral dysplasia and bladder cancer in cystectomy specimens. Br J Urol (1985) 0.80
Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J Clin Oncol (2011) 3.59
Urinary diversion. Urology (2007) 2.65
Benign retroperitoneal schwannoma: a case series and review of the literature. Urology (2003) 2.62
Detection of occult lymph node metastases in locally advanced node-negative prostate cancer. J Clin Oncol (2006) 2.55
Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results. J Urol (2004) 2.50
Superficial (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy. J Urol (2006) 2.01
Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol (2004) 2.00
Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer. J Urol (2006) 1.92
Neobladder with prostatic capsule and seminal-sparing cystectomy for bladder cancer: a step in the wrong direction. Urol Clin North Am (2005) 1.74
Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history. Rev Urol (2008) 1.58
Radical cystectomy in the elderly: Comparison of survival between younger and older patients. Cancer (2005) 1.55
EphB4 expression and biological significance in prostate cancer. Cancer Res (2005) 1.53
Combination of molecular alterations and smoking intensity predicts bladder cancer outcome: a report from the Los Angeles Cancer Surveillance Program. Cancer (2013) 1.51
Radical cystectomy for primary neuroendocrine tumors of the bladder: the university of southern california experience. J Urol (2005) 1.45
A novel precision-engineered microfiltration device for capture and characterisation of bladder cancer cells in urine. Eur J Cancer (2013) 1.45
Upper tract urothelial recurrence following radical cystectomy for transitional cell carcinoma of the bladder: an analysis of 1,069 patients with 10-year followup. J Urol (2007) 1.41
Radical cystectomy in the elderly: comparison of clincal outcomes between younger and older patients. Cancer (2005) 1.28
Salvage radical prostatectomy: quality of life outcomes and long-term oncological control of radiorecurrent prostate cancer. J Urol (2006) 1.16
Prognostic significance of lymphovascular invasion of bladder cancer treated with radical cystectomy. J Urol (2005) 1.13
Long-term outcome in patients with a Gleason score ≤ 6 prostate cancer treated by radical prostatectomy. BJU Int (2011) 1.10
The management of urethral transitional cell carcinoma after radical cystectomy for invasive bladder cancer. J Urol (2004) 1.10
A critical analysis of perioperative mortality from radical cystectomy. J Urol (2006) 1.10
Cystoprostatectomy and orthotopic ileal neobladder reconstruction for management of bacille Calmette Guérin-induced bladder contractures. Urology (2005) 1.06
Microscopic and gross extravesical extension in pathological staging of bladder cancer. J Urol (2004) 1.03
Pubovaginal slings for stress urinary incontinence following radical cystectomy and orthotopic neobladder reconstruction in women. J Urol (2004) 1.03
Open radical cystectomy with lymphadenectomy remains the treatment of choice for invasive bladder cancer. Curr Opin Urol (2007) 1.00
Surgery and adjunctive chemotherapy for invasive bladder cancer. Surg Oncol (2002) 1.00
Alpha blocker therapy for children with dysfunctional voiding and urinary retention. J Urol (2003) 0.97
Clinical outcomes and recurrence predictors of lymph node positive urothelial cancer after cystectomy. J Urol (2009) 0.96
Molecular pathways in bladder cancer. Urol Res (2004) 0.95
Surgical benchmarks for the treatment of invasive bladder cancer. Urol Oncol (2007) 0.91
Variability in surgical quality in a phase III clinical trial of radical cystectomy in patients with organ-confined, node-negative urothelial carcinoma of the bladder. J Surg Oncol (2015) 0.91
Natural history of surgically treated bladder carcinoma with extravesical tumor extension. Cancer (2003) 0.91
The impact of positive soft tissue surgical margins following radical cystectomy for high-grade, invasive bladder cancer. World J Urol (2008) 0.90
Usefulness of CA 125 as a preoperative prognostic marker for transitional cell carcinoma of the bladder. J Urol (2004) 0.88
Postchemotherapy residual masses in advanced seminoma: current management and outcomes. Expert Rev Anticancer Ther (2005) 0.88
Outcomes of locally advanced (T3 or greater) prostate cancer in men undergoing robot-assisted laparoscopic prostatectomy. J Endourol (2009) 0.87
Prognosis of seminal vesicle involvement by transitional cell carcinoma of the bladder. J Urol (2004) 0.85
Pathological guidelines for orthotopic urinary diversion in women with bladder cancer: a review of the literature. J Urol (2007) 0.85
Training the urologic oncologist of the future: where are the challenges? Urol Oncol (2009) 0.84
The prognostic and staging value of lymph node dissection in the treatment of invasive bladder cancer. Nat Clin Pract Urol (2006) 0.83
Superficial bladder cancer: part 1. Update on etiology, classification and natural history. Expert Rev Anticancer Ther (2006) 0.82
Angiomyolipoma with vena caval extension. Urology (2002) 0.82
T-pouch: a new valve design for a continent ileostomy. Dis Colon Rectum (2002) 0.82
Lymphadenectomy in bladder cancer: a review. Urol Int (2007) 0.82
New molecular markers for bladder cancer detection. Curr Opin Urol (2004) 0.82
Urethral foreign body management: a case report. ScientificWorldJournal (2004) 0.82
Risk factors and clinical outcomes of patients with node-positive muscle-invasive bladder cancer. Expert Rev Anticancer Ther (2008) 0.80
The evolving role of pelvic lymphadenectomy in the treatment of bladder cancer. Urol Oncol (2004) 0.80
Indications for early cystectomy. Urology (2003) 0.80
Contemporary concepts of radical cystectomy and the treatment of bladder cancer. J Urol (2003) 0.80
Superficial bladder cancer: part 2. Management. Expert Rev Anticancer Ther (2007) 0.78
Adjuvant chemotherapy for locally advanced urothelial carcinoma: an overview of the USC experience. World J Urol (2008) 0.78
Choosing earlier therapy for muscle-invasive bladder cancer. Rev Urol (2005) 0.78
Outcomes of radical cystectomy. BJU Int (2008) 0.77
Application of continuous tension to aid in performing the vesicourethral anastomosis for robot-assisted prostatectomy. J Endourol (2009) 0.77
Outcomes of patients with clinical CIS-only disease treated with radical cystectomy. World J Urol (2008) 0.77
Molecular prognostic factors in bladder cancer. BJU Int (2005) 0.77
The importance of an extended lymphadenectomy in the management of high-grade invasive bladder cancer. Expert Rev Anticancer Ther (2004) 0.76
Comparison of extraperitoneal and intraperitoneal augmentation enterocystoplasty for neurogenic bladder in spinal cord injury patients. World J Urol (2008) 0.76
Retroperitoneal lymph node dissection in the treatment of low-stage nonseminomatous germ cell tumors of the testicle: an update. Urol Oncol (2005) 0.76
Which treatment should patients with high-risk T1G3 bladder cancer receive? Nat Clin Pract Urol (2008) 0.75
Hemi-T pouch modification for pediatric urinary diversion. J Urol (2003) 0.75
The treatment of patients with bladder cancer: let's not forget the past! J Urol (2005) 0.75
Combined radical prostatectomy and bladder augmentation for concomitant prostate cancer and detrusor instability. Urology (2005) 0.75
Surgical considerations for elderly urologic oncology patients. Urol Oncol (2009) 0.75
Retroperitoneal lymph node dissection in the treatment of low-stage nonseminomatous germ cell tumors of the testicle. Expert Rev Anticancer Ther (2005) 0.75